DHR Stock Analysis: Danaher | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 137.442m USD | 12M Return: -2.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 723M
EPS Trend: -70.2%
Qual. Beats: 1
Rev. Trend: -57.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Danaher Corporation (NYSE: DHR) is a U.S.-based diversified manufacturer and marketer of professional, medical, research, and industrial products and services, with operations primarily in the United States, China, and other international markets. The company is classified within the Health Care sector (Health Care Equipment sub-industry) and operates through three core segments: Biotechnology, Life Sciences, and Diagnostics.
The Biotechnology segment supplies technologies, consumables, and services that support the development and manufacturing of therapeutics, including cell culture media, chromatography resins, filtration products, aseptic fill-finish solutions, single-use manufacturing hardware, and lab-scale protein purification and analytical tools. This segment serves the bioprocessing and biopharmaceutical production value chain, where demand is driven by the growth of biologics, biosimilars, and advanced therapy manufacturing.
The Life Sciences segment offers instruments and consumables such as mass spectrometers, flow cytometry systems, lab automation, centrifugation, microscopes, and genomic medicine products, marketed under well-known brands including Beckman Coulter, Leica Microsystems, Pall, Phenomenex, SCIEX, Abcam, Aldevron, IDT, and Molecular Devices. The portfolio reflects Danahers brand-ownership business model, in which it acquires and operates specialized life science brands serving research, academic, and pharmaceutical customers.
The Diagnostics segment provides clinical instruments, consumables, software, and services used by hospitals, physicians offices, reference laboratories, and critical care settings to diagnose disease and guide treatment decisions. This segment benefits from recurring revenue tied to installed instrument bases and ongoing consumable usage.
The company was incorporated in 1969 under the name Diversified Mortgage Investors, Inc. and was renamed Danaher Corporation in 1984. It is headquartered in Washington, D.C., and trades on the NYSE under the ticker DHR with a large-cap market capitalization.
- Bioprocessing order growth drives Biotechnology segment expansion
- Abcam acquisition expands protein research consumables revenue base
- China revenue softness and FX weigh on reported growth
| Net Income: 3.69b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.14 > 1.0 |
| NWC/Revenue: 26.13% < 20% (prev 12.09%; Δ 14.04% < -1%) |
| CFO/TA 0.08 > 3% & CFO 6.44b > Net Income 3.69b |
| Net Debt (14.1b) to EBITDA (6.64b): 2.12 < 3 |
| Current Ratio: 1.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (711.2m) vs 12m ago -1.33% < -2% |
| Gross Margin: 60.68% > 18% (prev 59.80%; Δ 0.88% > 0.5%) |
| Asset Turnover: 30.47% > 50% (prev 30.11%; Δ 0.36% > 0%) |
| Interest Coverage Ratio: 17.95 > 6 (EBIT TTM 4.59b / Interest Expense TTM 256.0m) |
| A: 0.08 (Total Current Assets 13.9b - Total Current Liabilities 7.46b) / Total Assets 83.5b |
| B: 0.57 (Retained Earnings 47.6b / Total Assets 83.5b) |
| C: 0.06 (EBIT TTM 4.59b / Avg Total Assets 81.3b) |
| D: 1.73 (Book Value of Equity 52.9b / Total Liabilities 30.6b) |
| Altman-Z'' = 4.56 = AA |
| DSRI: 0.85 (Receivables 3.82b/4.31b, Revenue 24.8b/23.8b) |
| GMI: 0.99 (GM 59.80% / 60.68%) |
| AQI: 0.94 (AQ_t 0.75 / AQ_t-1 0.80) |
| SGI: 1.04 (Revenue 24.8b / 23.8b) |
| TATA: -0.03 (NI 3.69b - CFO 6.44b) / TA 83.5b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 199.05 with a total of 3,847,598 shares traded. Over the past week, the price has changed by +0.57%, over one month by +8.62%, over three months by +5.20% and over the past year by -2.43%.
Current recommended Stop Loss: 192.10 (which is 3.5% or 1.3 ATR below the current price).
Danaher has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy DHR.
- StrongBuy: 18
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 242.3 | 21.7% |
P/E Trailing = 37.4884
P/E Forward = 23.4192
P/S = 5.5469
P/B = 2.6457
P/EG = 1.2661
Revenue TTM = 24.8b USD
EBIT TTM = 4.59b USD
EBITDA TTM = 6.64b USD
Long Term Debt = 17.6b USD (from longTermDebt, last quarter)
Short Term Debt = 923.0m USD (from shortTermDebt, last quarter)
Debt = 19.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.28b
Net Debt = 14.1b USD (calculated: Debt 19.8b - CCE 5.70b)
Enterprise Value = 152b USD (137b + Debt 19.8b - CCE 5.70b)
Interest Coverage Ratio = 17.95 (Ebit TTM 4.59b / Interest Expense TTM 256.0m)
EV/FCF = 28.63x (Enterprise Value 152b / FCF TTM 5.29b)
FCF Yield = 3.49% (FCF TTM 5.29b / Enterprise Value 152b)
FCF Margin = 21.35% (FCF TTM 5.29b / Revenue TTM 24.8b)
Net Margin = 14.89% (Net Income TTM 3.69b / Revenue TTM 24.8b)
Gross Margin = 60.68% ((Revenue TTM 24.8b - Cost of Revenue TTM 9.74b) / Revenue TTM)
Gross Margin QoQ = 60.34% (prev 58.00%)
Tobins Q-Ratio = 1.81 (Enterprise Value 152b / Total Assets 83.5b)
Interest Expense / Debt = 1.30% (Interest Expense 256.0m / Debt 19.8b)
Taxrate = 14.98% (650.0m / 4.34b)
NOPAT = 3.91b (EBIT 4.59b * (1 - 14.98%))
Current Ratio = 1.87 (Total Current Assets 13.9b / Total Current Liabilities 7.46b)
Debt / Equity = 0.37 (Debt 19.8b / totalStockholderEquity, last quarter 52.9b)
Debt / EBITDA = 2.12 (Net Debt 14.1b / EBITDA 6.64b)
Debt / FCF = 2.66 (Net Debt 14.1b / FCF TTM 5.29b)
Total Stockholder Equity = 52.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.54% (Net Income 3.69b / Total Assets 83.5b)
RoE = 7.06% (Net Income TTM 3.69b / Total Stockholder Equity 52.2b)
RoCE = 6.58% (EBIT 4.59b / Capital Employed (Equity 52.2b + L.T.Debt 17.6b))
RoIC = 5.16% (NOPAT 3.91b / Invested Capital 75.8b)
WACC = 6.65% (E(137b)/V(157b) * Re(7.45%) + D(19.8b)/V(157b) * Rd(1.30%) * (1-Tc(0.15)))
Discount Rate = 7.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.67 | Cagr: -2.11%
[DCF] Terminal Value 76.43% ; FCFF base≈5.14b ; Y1≈5.50b ; Y5≈6.61b
[DCF] Fair Price = 123.5 (EV 102b - Net Debt 14.1b = Equity 87.4b / Shares 707.8m; r=8.35% [WACC [floored]]; 5y FCF grow 7.94% → 2.50% )
EPS Correlation: -70.16 | EPS CAGR: -6.82% | SUE: 1.40 | # QB: 1
Revenue Correlation: -57.76 | Revenue CAGR: -3.00% | SUE: -0.29 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.84 | Chg30d=+0.27% | Revisions=+40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=2.06 | Chg30d=+1.62% | Revisions=+50% | Analysts=4
EPS current Year (2026-12-31): EPS=8.50 | Chg30d=+0.78% | Revisions=+50% | GrowthEPS=+9.0% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=9.24 | Chg30d=+1.64% | Revisions=+40% | GrowthEPS=+8.7% | GrowthRev=+8.9%
[Analyst] Revisions Ratio: +77% (up=10, down=0)